ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
April 03, 2020

TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020

Read More
April 03, 2020

TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020

Read More
March 30, 2020

Subscription to raise £1.5 million to fund expansion of R&D pipeline

Read More
February 28, 2020

Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document

Read More
February 17, 2020

Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market

Read More
February 06, 2020

ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor’s™ new international Phase III trial

Read More
December 19, 2019

Admission to trading on Euronext Growth Brussels

Read More
December 17, 2019

Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels

Read More
December 13, 2019

Dual listing on Euronext growth Brussels

Read More
December 11, 2019

Share price volatility

Read More
December 03, 2019

ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco

Read More
December 02, 2019

TR1 – Notification of major interest in shareholdings

Read More
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 24
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved